Results 191 to 200 of about 98,296 (378)

Epidemiology, Pathophysiology and Management of Atypical Femur Fractures: an Update. [PDF]

Curr Osteoporos Rep
Collins L, Nguyen HH, Milat F, Ebeling PR.   +3 more
europepmc   +1 more source

Oral bisphosphonates [PDF]

, 2000
Pierre Major, Allan Lipton, James R. Berenson, Gabriel N. Hortobágyi   +3 more
openalex   +1 more source

Composite Colloidal Gels Made of Bisphosphonate‐Functionalized Gelatin and Bioactive Glass Particles for Regeneration of Osteoporotic Bone Defects

, 2017
M. Diba, W. A. Camargo, Mariateresa Brindisi, Kambiz Farbod, Alexey Klymov, Stephan Schmidt, Matthew J. Harrington, L. Draghi, A. Boccaccini, J. Jansen, J. J. van den Beucken, S. Leeuwenburgh   +11 more
semanticscholar   +1 more source

Incidence and Characteristics of Hospital‐Acquired Pressure Injuries in Acute Palliative Care Patients: A Four‐Year Analysis

Journal of Clinical Nursing, EarlyView.
ABSTRACT Aim To describe the cumulative incidence and characteristics of hospital‐acquired pressure injury in acute palliative patients. Design Secondary data analysis of hospital‐acquired pressure injuries during 2019–2022. Methods The setting was a palliative care unit at a tertiary hospital in Queensland, Australia, including adult (≥ 18 years ...
Saroeun Ven, Michael Steele, Adam Burston, Paul Fulbrook, Josephine Lovegrove, Sandra Miles, Susan Prince   +6 more
wiley   +1 more source

Clinical, Bone Mineral Density and Spinal Remodelling Responses to Zoledronate Treatment in Chronic Recurrent Multifocal Osteomyelitis. [PDF]

Diagnostics (Basel)
Patel F, Davis PJC, Crabtree N, Uday S.
europepmc   +1 more source

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis. [PDF]

Arthritis Rheumatol
Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...
Adami G, Saag KG.
europepmc   +2 more sources

Bisphosphonate and Bone Metastasis.

, 1998
Mitsuru Koizumi
openalex   +2 more sources

Systems biology strategy for drug potentiating through drug repurposing:bisphosphonates beyond osteoporosis treatment [PDF]

, 2018
Goltsov, Alexey, Kowalczyk, Zuzanna, Papineni, Rao V. L.   +2 more
core   +2 more sources

Incidence and Risk Factors of Peri‐Implantitis Over Time—A Prospective Cohort Study

Journal of Periodontal Research, EarlyView.
Identifying true risk factors requires a longitudinal evaluation to verify the temporality criterion. This study identified periodontitis (stage and grade), lifestyle behaviours (smoking and sleep duration), implant location, and prosthetic factors (restoration type and margin location) as risk factors for peri‐implantitis.
Mario Romandini, Cristina Lima, Diogo Banaco, Rita Azevedo, Mariano Sanz   +4 more
wiley   +1 more source

Perioperative Denosumab Versus Bisphosphonates for MIDLF Surgery in Patients With Osteopenia: A Short-Term Prospective Cohort Study. [PDF]

Global Spine J
Changsheng H, Yue L, Wang S, Sun H.
europepmc   +1 more source